文献速递肾癌与肾肿瘤

转移性肾细胞癌伴或不伴肉瘤样特征患者一线系统治疗的临床结局真实世界评估

Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies.
PubMed 文献 · Eur Urol Oncol · 2023-12-13

研究利用加拿大肾癌信息系统数据,纳入2011年1月至2022年12月诊断的1202例IMDC中高危转移性肾细胞癌患者,比较一线靶向治疗(TT)与免疫治疗(IO)的生存结局。非肉瘤样患者中IO组中位OS 72个月 vs TT组48个月(HR 0.63,95%CI 0.50-0.80),肉瘤样患者中IO组中位OS 48个月 vs TT组18个月(HR 0.41,95%CI 0.26-0.64)。IO治疗与改善生存相关,肉瘤样患者获益幅度更大。

要点

  • 非肉瘤样mRCC患者中,IO组中位OS 72个月 vs TT组48个月(HR 0.63,95%CI 0.50-0.80)。
  • 肉瘤样mRCC患者中,IO组中位OS 48个月 vs TT组18个月(HR 0.41,95%CI 0.26-0.64)。
  • 肉瘤样患者中IO组ORR 49.5% vs TT组13.8%,非肉瘤样患者中IO组38.5% vs TT组23.5%。

核心结论

  • IO治疗与mRCC患者改善生存相关,肉瘤样mRCC患者获益幅度更大;早期识别肉瘤样状态可能有助于医疗提供者做出更好的治疗决策。

研究设计与样本

  • 利用加拿大肾癌信息系统(CKCis)识别2011年1月至2022年12月诊断的IMDC中危或高危转移性肾细胞癌患者,均接受一线系统治疗且肾切除标本有肉瘤样特征存在与否的组织学记录。
  • 共纳入1202例 eligible 患者,按初始治疗分为靶向治疗(TT)单用791例和免疫治疗(IO)为基础的系统治疗(IO-IO或IO-TT联合)411例。
  • 采用倾向评分逆概率治疗加权平衡协变量,Cox比例风险模型评估初始治疗对总生存(OS)的影响。

主要发现

  • 1202例患者中76%为男性,91%在系统治疗前接受过肾切除术。
  • 非肉瘤样患者(TT组639例,IO组320例):IO组中位OS 72个月 vs TT组48个月(HR 0.63,95%CI 0.50-0.80),ORR IO组38.5% vs TT组23.5%。
  • 肉瘤样患者(TT组152例,IO组91例):IO组中位OS 48个月 vs TT组18个月(HR 0.41,95%CI 0.26-0.64),ORR IO组49.5% vs TT组13.8%。
  • 仅在同时性转移性疾病患者中观察到相似结果。

临床怎么用

  • 作者认为,IO治疗与mRCC患者改善生存相关,肉瘤样mRCC患者获益幅度更大,早期识别肉瘤样状态可能有助于医疗提供者做出更好的治疗决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Metastatic renal cell carcinoma (mRCC) patients have been reported to have better outcomes when treated with immunotherapies (IO) compared to targeted therapies (TT). This study aims to evaluate the impact of first-line systemic therapies on survival of mRCC patients with or without sarcomatoid features using real-world data. METHODS: Metastatic RCC patients of International mRCC Database Consortium (IMDC) intermediate or high risk, diagnosed from January 2011 to December 2022, treated with first-line systemic therapies, and with histological documentation of the presence or absence of sarcomatoid features in nephrectomy specimens were identified using the Canadian Kidney Cancer information system. Patients were classified by initial treatment: (1) targeted therapy (TT) used alone or (2) immunotherapy (IO)-based systemic therapies used in combination of either IO-IO or IO-TT. The inverse probability of treatment weighting using propensity scores was used to balance for covariates. Cox proportional hazard models were used to assess the impact of initial treatment received on overall survival (OS). KEY FINDINGS AND LIMITATIONS: Of the 1202 eligible patients, 791 were treated with TT and 411 with IO combinations. Of the patients, 76% were male, and the majority (91%) had a nephrectomy before systemic therapy. In nonsarcomatoid patients (639 TT and 320 IO patients), treatment with IO was associated with improved OS compared with patients treated with TT (median of 72 vs 48 mo, hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.50-0.80, objective response rate [ORR] of 38.5% for IO and 23.5% for TT). In sarcomatoid patients (152 TT and 91 IO patients), treatment with IO was associated with improved OS (median of 48 vs 18 mo, HR 0.41, 95% CI 0.26-0.64, ORR of 49.5% for IO and 13.8% for TT). Similar results were observed in patients with synchronous metastatic disease only. CONCLUSIONS AND CLINICAL IMPLICATIONS: IO treatment was associated with improved survival in mRCC patients. The magnitude of benefit is increased in patients with sarcomatoid mRCC, consequently, identifying the sarcomatoid status early on could help healthcare providers make a better treatment decision. PATIENT SUMMARY: Metastatic renal cell carcinoma (mRCC) patients of International mRCC Database Consortium intermediate and high risk, diagnosed from January 2011 to December 2022, treated with first-line systemic therapies, and with histological documentation of the presence or absence of sarcomatoid features in nephrectomy specimens were identified using the Canadian Kidney Cancer information system (CKCis). In this study, treatment with immunotherapy was associated to an improved survival and response rates for mRCC patients with and without sarcomatoid features. The magnitude of benefit is increased in patients with sarcomatoid mRCC.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Sawaya GB, Dragomir A, Wood LA, et al. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies. Eur Urol Oncol. 2023. PMID: 38097481. doi:10.1016/j.euo.2023.11.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。